Phase 1 Safety of ICOS Agonist Antibody JTX-2011 Alone and with Nivolumab in Advanced Solid Tumors

Collaboration with Jounce - Presented at ASCO Annual Meeting 2017


In this collaboration with Jounce Therapeutics, we developed a quantitative systems pharmacology (QSP) model describing target binding by JTX-2011 and target mediated drug disposition in blood, tumor and non-tumor tissues based on preclinical potency and non-linear PK data across species. The model was translated to predict PK and target engagement (TE) in humans to facilitate dose selection. The QSP model predicted >95% TE for 21 days at the top planned dose. 

Leave site to view poster >>